呼吸系統感染疾病診斷的全球市場:各技術，複合體，場所，各產品，各地區:附執行顧問指南(2025年～2029年)

COVID-19 開闢了呼吸道感染的 POC 檢測市場。市佔率之爭即將進入白熱化階段。一個巨大的新市場正在開放。我們不要忘記不僅篩檢新冠病毒，還篩檢 20 多種其他呼吸道病原體的市場。

新技術正在徹底改變呼吸道感染的診斷。縮短獲得結果的時間所開闢的市場規模是目前基於微生物學的實踐的許多倍。

呼吸道感染十分普遍（年輕人每年最多罹患八次感冒），因此潛在市場規模龐大。呼吸道疾病已經是最大的傳染病類別，而且規模可能會增加一倍。這對所有診斷公司來說都是一個成長機會。

本報告提供全球呼吸系統感染疾病診斷市場相關調查，提供市場概要，以及各技術，複合體，場所，各產品，地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 市場指南

第2章 簡介和市場定義

• 呼吸系統感染疾病是什麼
• 診斷和治療所扮演的角色
• 市場定義
• 調查手法
• 觀點:醫療保健和IVD產業

第3章 市場概要

• 市場進入機關
  • 學術研究機關
  • 診斷測試開發商
  • 儀器供應商
  • 藥品·試劑廠商
  • 病理供應商
  • 獨立型臨床檢驗室
  • 公共的國立/地區研究所
  • 醫院檢驗室
  • 臨床檢驗室
  • 審核機關
  • 認證機關
• 呼吸系統感染疾病
• 診斷- 變化的作用
• COVID-19
• 大流行病診斷

第4章 市場趨勢

• 成長促進因素
• 阻礙成長的要素
• 測量與自動化
• 診斷技術開發

第5章 呼吸系統感染疾病診斷的最近的趨勢

第6章 主要企業的簡介

• Abacus Diagnostica
• Abbott Laboratories
• Accelerate Diagnostics
• Access Bio
• Ador Diagnostics
• ADT Biotech
• Akonni Biosystems
• Altona Diagnostics
• Alveo Technologies
• Anatolia Geneworks
• Antelope Dx
• Applied BioCode
• Assurance Scientific Laboratories
• Aureum Diagnostics
• Aus Diagnostics
• Beckman Coulter Diagnostics
• Becton, Dickinson and Company
• Binx Health
• Biocartis
• BioFire Diagnostics(bioMerieux)
• bioMerieux Diagnostics
• Bio-Rad Laboratories, Inc.
• Bosch Healthcare Solutions GmbH
• Celemics
• Cepheid(Danaher)
• Chembio
• Co Diagnostics
• Credo Diagnostics Biomedical
• Cue Health
• Curetis N.V./Curetis GmbH
• Detect
• Diagenode Diagnostics
• Diascopic
• Diasorin S.p.A.
• Enzo Biochem
• Eurofins Scientific
• Fluxergy
• Fulgent Genetics
• Fusion Genomics.
• Genetic Signatures
• GenMark Dx(Roche)
• Hibergene Diagnostics
• Hologic
• Immunexpress
• Inflammatix
• Invetech
• Janssen Diagnostics
• Karius
• Lexagene
• LightDeck Diagnostics
• Luminex Corp
• Lumos Diagnostics
• Mammoth Biosciences
• Maxim Biomedical
• Meridian Bioscience
• Mesa Biotech(Thermo Fisher)
• Millipore Sigma
• Mindray
• Mobidiag(Hologic)
• Mologic
• Nanomix
• Operon
• Oxford Nanopore Technologies
• Panagene
• Perkin Elmer
• Prenetics
• Primerdesign(Novacyt)
• Prominex
• Qiagen
• QuantuMDx
• QuidelOrtho
• Roche Molecular Diagnostics
• Seegene
• Siemens Healthineers
• Sona Nanotech
• SpeeDx
• T2 Biosystems
• Talis Biomedical
• Thermo Fisher Scientific Inc.
• Veramarx
• Veredus Laboratories
• Visby Medical
• XCR Diagnostics
• Zhejiang Orient Gene Biotech

第7章 全球呼吸系統感染疾病診斷市場

• 全球市場 - 各國
• 全球市場 - 各技術
• 全球市場 - 各複合體
• 全球市場 - 概要，各地區
• 全球市場 - 概要，各產品

第8章 全球呼吸系統感染疾病診斷市場- 各技術

• 微生物學
• PCR
• NGS
• 免疫檢測法/其他
• C19單複合體

第9章 全球呼吸系統感染疾病診斷市場- 複合體

• C19單複合體
• 單複合體
• 雙層/三層
• 多工

第10章 全球呼吸系統感染疾病診斷市場- 各地區

• 醫院研究室
• 門診病人檢驗室
• POC
• 其他

第11章 全球呼吸系統感染疾病診斷市場- 各產品

• 設備
• 消耗品
• 軟體和服務

第12章 附錄

Report Overview:

COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. And lets not forget the screening market, not just for COVID, but for the rest of the 20 something respiratory pathogens as well. Multiplex vs single plex? Explore the rapidly changing market as competitors jockey for position in new markets that are not yet well understood.

New technology is forever changing the diagnosis of respiratory infections. Shrinking time to result is opening up markets multiple times the size of current microbiology based practice. The Laboratory has already moved into the Emergency Room.

The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory, already the largest infectious disease category could multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this in depth report.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

• 1.1. Situation Analysis
• 1.2. Guide for Executives and Business Development Staff
• 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

• 2.1. What are Respiratory Infections?
• 2.2. The Role of Diagnosis & Treatment
• 2.3. Market Definition
  • 2.3.1. Revenue Market Size
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare and the IVD Industry
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Diagnostics
  • 2.5.3. Important Role of Insurance for Diagnostics

3. Market Overview

• 3.1. Players in a Dynamic Market
  • 3.1.1. Academic Research Lab
  • 3.1.2. Diagnostic Test Developer
  • 3.1.3. Instrumentation Supplier
  • 3.1.4. Chemical/Reagent Supplier
  • 3.1.5. Pathology Supplier
  • 3.1.6. Independent Clinical Laboratory
  • 3.1.7. Public National/regional Laboratory
  • 3.1.8. Hospital Laboratory
  • 3.1.9. Physicians Office Lab (POLS)
  • 3.1.10. Audit Body
  • 3.1.11. Certification Body
• 3.2. Respiratory Infections
  • 3.2.1. Upper vs. Lower - Marketing Implications
  • 3.2.2. Understanding the Role of Pneumonia
  • 3.2.3. Bacterial Infections
    • 3.2.3.1. Streptococcal Infections
    • 3.2.3.2. Acute Otitis Media
    • 3.2.3.3. Bacterial Rhinosinusitis
    • 3.2.3.4. Diphtheria
    • 3.2.3.5. Pneumococcal Pneumonia
    • 3.2.3.6. Haemophilus Pneumonia
    • 3.2.3.7. Mycoplasma Pneumonia (Walking Pneumonia)
    • 3.2.3.8. Chlamydial Pneumonias and Psittacosis
    • 3.2.3.9. Health Care-Associated Pneumonia
    • 3.2.3.10. Pseudomonas Pneumonia
    • 3.2.3.11. Legionnaires Disease
  • 3.2.4. Tuberculosis - A Special Case
  • 3.2.5. Viral Infections
    • 3.2.5.1. The Common Cold
    • 3.2.5.2. Influenza
    • 3.2.5.3. Viral Pneumonia
    • 3.2.5.4. SARS and MERS
    • 3.2.5.5. Measles (Rubeola)
    • 3.2.5.6. Rubella (German Measles)
    • 3.2.5.7. Chickenpox and Shingles
  • 3.2.6. Fungal and Other Pathogens
    • 3.2.6.1. Histoplasmosis
    • 3.2.6.2. Coccidioidomycosis
    • 3.2.6.3. Blastomycosis
    • 3.2.6.4. Mucormycosis
    • 3.2.6.5. Aspergillosis
    • 3.2.6.6. Pneumocystis Pneumonia
    • 3.2.6.7. Cryptococcosis
• 3.3. Diagnostics - A Changing Role
  • 3.3.1. Historical Practice
  • 3.3.2. Current Diagnostics
  • 3.3.3. The Multiplex Vector
  • 3.3.4. Future Diagnostics - The Question of When and Where
  • 3.3.5. Respiratory Infection Diagnostics - The Destination
  • 3.3.6. Diagnostics as Defensive Weapons
• 3.4. COVID-19
  • 3.4.1. Signs and symptoms
  • 3.4.2. Transmission
  • 3.4.3. Diagnosis
  • 3.4.4. Prevention
  • 3.4.5. Management
  • 3.4.6. Prognosis
• 3.5. Pandemic Diagnostics
  • 3.5.1. Risk Management - Spark and Spread
  • 3.5.2. Dx Technology - Nucleic Acid Based
  • 3.5.3. Dx Technology - Immunoassay & Serology
  • 3.5.4. Time to Market and Preparedness Issues
  • 3.5.5. Unrecognized Role of Multiplex in Pandemic Mangement

4. Market Trends

• 4.1. Factors Driving Growth
  • 4.1.1. Syndromic Multiplexing
  • 4.1.2. T.A.T.
  • 4.1.3. Antimicrobial Resistance Movement
  • 4.1.4. Pandemic Mitigation
  • 4.1.5. An Aging at Risk Population
• 4.2. Factors Limiting Growth
  • 4.2.1. The Cost Curve
  • 4.2.2. Regulation and coverage
  • 4.2.3. Laissez Faire
• 4.3. Instrumentation and Automation
  • 4.3.1. The Shrinking Multiplexing Machine
  • 4.3.2. Bioinformatics Networking and Anonymous Reporting
• 4.4. Diagnostic Technology Development
  • 4.4.1. The Key Role of Time to Result
  • 4.4.2. Single Cell Genomics Changes the Picture
  • 4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment

5. Respiratory Infection Diagnostics Recent Developments

• 5.1. Recent Developments - Importance and How to Use This Section
  • 5.1.1. Importance of These Developments
  • 5.1.2. How to Use This Section
• 5.2. Qiagen Respiratory Mini Panel Approved
• 5.3. Co-Diagnostics Submits At-Home PCR System to FDA
• 5.4. AMDI scores $5.3m NIH grant for Rapid POC Panel
• 5.5. Roche Gets Multiplex Emergency Use Authorization
• 5.6. ReadyGo Diagnostics, Gemina Labs Pursue Respiratory Market
• 5.7 3EO Health to Launch Molecular Point-of-Care Device
• 5.8. Delve Bio to Commercialize Metagenomic Pathogen Test
• 5.9. Sensible Diagnostics Nabs Award for Respiratory Panel
• 5.10. BD - FDA Clearance for Combo Respiratory Test
• 5.11. Co-Diagnostics Awarded for Upper Respiratory Panel
• 5.12. FDA Authorizes Cue Health C19 At-Home MDx
• 5.13. BioMerieux Waiver for Respiratory Mini Panel
• 5.14. Aptitude Medical Systems Aiming for At-Home Market
• 5.15. SD Biosensor Eyes Global Expansion For Rapid MDx System
• 5.16. New bioMerieux Respiratory Diagnostic System
• 5.17. Visby Medical Nabs FDA EUA for POC Respiratory Panel Test
• 5.18. SENZO SECURES FUNDING FOR PCR-ACCURATE LATERAL FLOW TEST
• 5.19. Takara Bio USA, BioExcel Diagnostics Partner for Dx Panels
• 5.20. ProtonDx's Dragonfly Dx System successfully deployed
• 5.21. Genomtec Gets CE-IVD Mark for POC Respiratory Disease Test
• 5.22. FDA Issues First EUA for Non-Prescription COVID-19/Flu/RSV Test
• 5.23. "Diagnostics for the Real World" Plans Third-Generation POC Platform
• 5.24. Cue Health Targets DTC Market
• 5.25. Investors Skeptical of Ortho Clinical Diagnostics Acquisition by Quidel
• 5.26. Sense Biodetection to Debut Instrument-Free POC MDx
• 5.27. LGC Develops 'Ultra-High-Throughput' COVID Workflow
• 5.28. Cue Health Files for IPO for up to $100M
• 5.29. QuantuMDx Developing Multiplex System, Syndromic Panels
• 5.30. Bio-Rad Laboratories Gets CE Mark for Respiratory RT-PCR Assay Kit
• 5.31. BforCure Preparing Multiple Panels for PoC qPCR Platform
• 5.32. Angstrom Bio Raises $3M in Private Financing
• 5.33. Test for Them All
• 5.34. Hologic Banking on MDx Acquisitions
• 5.35. Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
• 5.36. Talis Biomedical 2020 Revenues Rise Sharply
• 5.37. Luminex to Develop Covid/Flu/RSV Test
• 5.38. Becton Dickinson Charts Transition of COVID Diagnostics
• 5.39. MiRxes Receives Approval for Multiplex Covid/Flu Test
• 5.40. New Silicon-Based Test for Infectious Disease Screening
• 5.41. GenMark to Meet Demand for Respiratory Panel
• 5.42. Tempus Announces COVID-19 Testing, Data Initiative
• 5.43. Abacus Diagnostica Readying Multiplex Respiratory Test
• 5.44. Qiagen Acquires NeuMoDx Molecular
• 5.45. Companies Shift to Multiplex Tests for SARS-CoV-2, Influenza
• 5.46. Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel
• 5.47. Cepheid Debuts 10-Color Technology With New Tuberculosis Test
• 5.48. BioMerieux's Pneumonia Panel Could Improve Care
• 5.49. Mammoth Biosciences Announces CRISPR-Based C19 Diagnostic
• 5.50. Genetic Signatures Gets CE Mark for C19 Molecular Test
• 5.51. Qiagen Respiratory Panel with C19 Receives CE Mark
• 5.52. Lumos Diagnostics Closes $15M Series A Funding
• 5.53. Fusion Genomics to Assess NGS Respiratory Tract Assay

6. Profiles of Key Players

• 6.1. Abacus Diagnostica
• 6.2. Abbott Laboratories
• 6.3. Accelerate Diagnostics
• 6.4. Access Bio
• 6.5. Ador Diagnostics
• 6.6. ADT Biotech
• 6.7. Akonni Biosystems
• 6.8. Altona Diagnostics
• 6.9. Alveo Technologies
• 6.10. Anatolia Geneworks
• 6.11. Antelope Dx
• 6.12. Applied BioCode
• 6.13. Assurance Scientific Laboratories
• 6.14. Aureum Diagnostics
• 6.15. Aus Diagnostics
• 6.16. Beckman Coulter Diagnostics
• 6.17. Becton, Dickinson and Company
• 6.18. Binx Health
• 6.19. Biocartis
• 6.20. BioFire Diagnostics (bioMerieux)
• 6.21. bioMerieux Diagnostics
• 6.22. Bio-Rad Laboratories, Inc.
• 6.23. Bosch Healthcare Solutions GmbH
• 6.24. Celemics
• 6.25. Cepheid (Danaher)
• 6.26. Chembio
• 6.27. Co Diagnostics
• 6.28. Credo Diagnostics Biomedical
• 6.29. Cue Health
• 6.30. Curetis N.V. / Curetis GmbH
• 6.31. Detect
• 6.32. Diagenode Diagnostics
• 6.33. Diascopic
• 6.34. Diasorin S.p.A.
• 6.35. Enzo Biochem
• 6.36. Eurofins Scientific
• 6.37. Fluxergy
• 6.38. Fulgent Genetics
• 6.39. Fusion Genomics.
• 6.40. Genetic Signatures
• 6.41. GenMark Dx (Roche)
• 6.42. Hibergene Diagnostics
• 6.43. Hologic
• 6.44. Immunexpress
• 6.45. Inflammatix
• 6.46. Invetech
• 6.47. Janssen Diagnostics
• 6.48. Karius
• 6.49. Lexagene
• 6.50. LightDeck Diagnostics
• 6.51. Luminex Corp
• 6.52. Lumos Diagnostics
• 6.53. Mammoth Biosciences
• 6.54. Maxim Biomedical
• 6.55. Meridian Bioscience
• 6.56. Mesa Biotech (Thermo Fisher)
• 6.57. Millipore Sigma
• 6.58. Mindray
• 6.59. Mobidiag (Hologic)
• 6.60. Mologic
• 6.61. Nanomix
• 6.62. Operon
• 6.63. Oxford Nanopore Technologies
• 6.64. Panagene
• 6.65. Perkin Elmer
• 6.66. Prenetics
• 6.67. Primerdesign (Novacyt)
• 6.68. Prominex
• 6.69. Qiagen
• 6.70. QuantuMDx
• 6.71. QuidelOrtho
• 6.72. Roche Molecular Diagnostics
• 6.73. Seegene
• 6.74. Siemens Healthineers
• 6.75. Sona Nanotech
• 6.76. SpeeDx
• 6.77. T2 Biosystems
• 6.78. Talis Biomedical
• 6.79. Thermo Fisher Scientific Inc.
• 6.80. Veramarx
• 6.81. Veredus Laboratories
• 6.82. Visby Medical
• 6.84. XCR Diagnostics
• 6.85. Zhejiang Orient Gene Biotech

7. The Global Market for Respiratory Infection Diagnostics

• 7.1. Global Market by Country
  • 7.1.1. Table - Global Market by Country
  • 7.1.2. Chart - Global Market by Country
• 7.2. Global Market by Technology - Overview
  • 7.2.1. Table - Global Market by Technology
  • 7.2.2. Chart - Global Market by Technology - Base/End Year Comparison
  • 7.2.3. Chart - Global Market by Technology - Base Year
  • 7.2.4. Chart - Global Market by Technology - End Year
  • 7.2.5. Chart - Global Market by Technology - Share by Year
  • 7.2.6. Chart - Global Market by Technology - Segment Growth
• 7.3. Global Market by Plex - Overview
  • 7.3.1. Table - Global Market by Plex
  • 7.3.2. Chart - Global Market by Plex - Base/End Year Comparison
  • 7.3.3. Chart - Global Market by Plex - Base Year
  • 7.3.4. Chart - Global Market by Plex - End Year
  • 7.3.5. Chart - Global Market by Plex - Share by Year
  • 7.3.6. Chart - Global Market by Plex - Segment Growth
• 7.4. Global Market by Place - Overview
  • 7.4.1. Table - Global Market by Place
  • 7.4.2. Chart - Global Market by Place - Base/End Year Comparison
  • 7.4.3. Chart - Global Market by Place - Base Year
  • 7.4.4. Chart - Global Market by Place - End Year
  • 7.4.5. Chart - Global Market by Place - Share by Year
  • 7.4.6. Chart - Global Market by Place - Segments Growth
• 7.5. Global Market by Product - Overview
  • 7.5.1. Table - Global Market by Product
  • 7.5.2. Chart - Global Market by Product - Base/End Year Comparison
  • 7.5.3. Chart - Global Market by Product - Base Year
  • 7.5.4. Chart - Global Market by Product - End Year
  • 7.5.5. Chart - Global Market by Product - Share by Year
  • 7.5.6. Chart - Global Market by Product - Segments Growth

8. Global Respiratory Infection Diagnostic Markets - By Technology

• 8.1. Microbiology
  • 8.1.1. Table Microbiology - by Country
  • 8.1.2. Chart - Microbiology Growth
• 8.2. PCR
  • 8.2.1. Table PCR - by Country
  • 8.2.2. Chart - PCR Growth
• 8.3. NGS
  • 8.3.1. Table NGS - by Country
  • 8.3.2. Chart - NGS Growth
• 8.4. Immunoassay/Other
  • 8.4.1. Table Immunoassay - by Country
  • 8.4.2. Chart - Immunoassay/Other Growth
• 8.5. C19 Singleplex
  • 8.5.1. Table C19splex - by Country
  • 8.5.2. Chart - C19splex Growth

9. Global Respiratory Infection Diagnostic Markets - by Plex

• 9.1. C19 Single Plex
  • 9.1.1. Chart - C19 Single Plex Growth
• 9.2. Singleplex
  • 9.2.1. Table Singleplex - by Country
  • 9.2.2. Chart - Singleplex Growth
• 9.3. Duplex/Triplex
  • 9.3.1. Table Duplex/Triplex - by Country
  • 9.3.2. Chart - Duplex/Triplex Growth
• 9.4. Multiplex Technology
  • 9.4.1. Table Multiplex - by Country
  • 9.4.2. Chart - Multiplex Growth

10. Global Respiratory Infection Diagnostic Markets - by Place

• 10.1. Hospital Lab
  • 10.1.1. Table Hospital Lab - by Country
  • 10.1.2. Chart - Hospital Lab Growth
• 10.2. Outpatient Lab
  • 10.2.1. Table Outpatient Lab - by Country
  • 10.2.2. Chart - Outpatient Lab Growth
• 10.3. POC
  • 10.3.1. Table POC - by Country
  • 10.3.2. Chart - POC Growth
• 10.4. Other Technology
  • 10.4.1. Chart - Other Growth

11. Global Respiratory Infection Diagnostic Markets - by Product

• 11.1. Instruments
  • 11.1.1. Table Instruments - by Country
  • 11.1.2. Chart - Instruments Growth
• 11.2. Consumables
  • 11.2.1. Table Consumables - by Country
  • 11.2.2. Chart - Consumables Growth
• 11.3. Software & Service
  • 11.3.1. Table Software & Service - by Country
  • 11.3.2. Chart - Software & Service Growth

12. Appendices

• 12.1. United States Medicare System: Clinical Laboratory Fees Schedule
• 12.2. The Most Used IVD Assays
• 12.3. The Highest Grossing Assays

Table of Tables

• Table 1: Market Players by Type
• Table 2: Bacterial Causes of Pneumonia
• Table 3: List of Influenza Pandemics
• Table 4: Viral Infections of the Respiratory Tract
• Table 5: Fungal Infections of the Respiratory Tract
• Table 6: Characteristics of Coronavirus Pandemic Infections
• Table 7: COVID-19 Symptoms
• Table 8: Five Factors Driving Growth
• Table 9: Three Factors Limiting Growth
• Table 10: Key Diagnostic Laboratory Technology Trends
• Table 11 - Global Market by Region
• Table 12: Global Market by Technology
• Table 13: Global Market by Plex
• Table 14: Global Market by Place
• Table 15: Global Market by Product
• Table 16: Microbiology by Country
• Table 17: PCR by Country
• Table 18: NGS by Country
• Table 19: Immunoassay/Other by Country
• Table 20: C19splex by Country
• Table 21: C19 Single Plex by Country
• Table 22: Singleplex by Country
• Table 23: Duplex/Triplex by Country
• Table 24: Multiplex by Country
• Table 25: Hospital Lab by Country
• Table 26: Outpatient Lab by Country
• Table 27: POC by Country
• Table 28: Other by Country
• Table 29: Instruments by Country
• Table 30: Consumables by Country
• Table 31: Software & Service by Country
• Table 32: Laboratory Fee Schedule
• Table 33: The Most Common Assays
• Table 34: Largest Revenue Assays

Table of Figures

• Figure 1: Respiratory Tract Infections
• Figure 2: The LRI Mortality Rate Globally
• Figure 3: Global Pandemic Pathogen Status
• Figure 4: Global Healthcare Spending
• Figure 5: The Lab Test Pie
• Figure 6: The Road to Diagnostics
• Figure 7: The BioFire Respiratory Panel
• Figure 8: Pneumonia
• Figure 9: Bacterial Infections of the Respiratory Tract
• Figure 10: The Development Cycle of Tuberculosis
• Figure 11: A Flu Epidemic in Europe - Historical Pattern
• Figure 12: The Single Multiplex Shift
• Figure 13: Percentage of World Population Over 65
• Figure 14: Global Market Share Chart
• Figure 15: Global Market by Technology - Base vs. End Year
• Figure 16: Global Market by Technology Base Year
• Figure 17: Global Market by Technology End Year
• Figure 18: Technology Share by Year
• Figure 19: Technology Segments Growth
• Figure 20: Plex - Base vs. End Year Segment Shift
• Figure 21: Plex Market Base Year
• Figure 22: Plex Market End Year
• Figure 23: Plex Share by Year
• Figure 24: Plex Segments Growth
• Figure 25: Place - Base vs. End Year
• Figure 26: Place Market Base Year
• Figure 27: Place Market End Year
• Figure 28: Place Share by Year
• Figure 29: Place Segments Growth
• Figure 30: Product - Base vs. End Year
• Figure 31: Product Market Base Year
• Figure 32: Product Market End Year
• Figure 33: Product Share by Year
• Figure 34: Product Segments Growth
• Figure 35: Microbiology Growth
• Figure 36: PCR Diagnostics Growth
• Figure 37: NGS Growth
• Figure 38: Immunoassay/Other Growth
• Figure 39: C19splex Growth
• Figure 40: C19 Single Plex Growth
• Figure 41: Singleplex Growth
• Figure 42: Duplex/Triplex Growth
• Figure 43: Multiplex Growth
• Figure 44: Hospital Lab Growth
• Figure 45: Outpatient Lab Growth
• Figure 46: POC Growth
• Figure 47: Other Growth
• Figure 48: Instruments Growth
• Figure 49: Consumables Growth
• Figure 50: Software & Service Growth